



CIF A-18.758.300  
Avda de la Innovación, n 1  
Edificio BIC (Ofic 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
Tel: 958 750 598

Mercado Alternativo Bursátil  
Plaza de la Lealtad, 1  
28014 MADRID

Granada, 14 December 2015

### RELEVANT FACT NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information about Neuron Bio, S.A. (hereinafter “NEURON” or “Company”).

The Board of Directors of Neuron Bio, S.A. resolved the following at its meeting of 10 December last:

- a) With regard to the relevant fact communicated to MAB on 16 March 2015 related to a patent application on an Alzheimer’s diagnostic tool it is said,

**“Considering the relevance of this scientific advance, the Board of Directors will evaluate different alternatives and business strategies that this Alzheimer’s disease diagnostic tool offers the company. The Board of Directors shall inform the MAB regularly on decisions taken and where applicable shall submit them to its shareholders.”**

- b) After relevant changes in the balance sheet during 2015, and concretely the value enhancement of its asset, the invested company Neol Biosolutions and the segregation in a subsidiary named Kalamata of its new biotechnological center, which will allow them the provision of services to third parties and,  
c) After the scientific advances reached in 2015, particularly the study of international commercial potential of the Alzheimer’s diagnostic tools

The Board of Directors of Neuron Bio has decided to write a new Business Plan containing the following strategic objectives to be presented in the market in January:

1. To concentrate obtaining revenues through the R&D service provision to third parties in its new facilities that will be operational in the second trimester of 2016.
2. To commercially exploit the diagnostic tool for the Alzheimer’s disease patented by the company through the medical network. Initially it will be exploited in Spain and then



CIF A-18.758.300  
Avda de la Innovación, n 1  
Edificio BIC (Ofic 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
Tel: 958 750 598

will be extended to the North American market through its subsidiary Neuron Bio USA Inc.

3. To raise financial resources in order to develop successfully its Strategic Plan by strengthening its own resources and its capital structure.

To this end the Board of Directors has adopted the following:

- To carry out a capital increase of €1,040,625 addressed to its shareholders. Terms of this capital increase are the amount of one (1) new share for every 8 previously issued at its nominal value of €1.
- To negotiate the entry of a private investor in the company's capital that contributes €3,000,000 to its own resources. For this purpose the Board of Directors will call an Extraordinary Shareholders' Meeting to submit for approval this operation, thus facilitating the entry for stable long-term partners strengthening its shareholder structure.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate  
Chairman of the Board of Directors